- Modulation of adenylyl cyclase activity in young and adult rat brain cortex. Identification of suramin as a direct inhibitor of adenylyl cyclase.2005 | Publication without faculty affiliation
- Mycobacterium tuberculosis enoyl-acyl carrier protein reductase inhibitors as potential antituberculotics: development in the past decade2015 | Faculty of Pharmacy in Hradec Králové
- Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?2021 | Faculty of Medicine in Hradec Králové
- Introduction to commentary on rivaroxaban +12009 | Faculty of Medicine in Hradec Králové
- The pharmacological profile of apixaban2013 | First Faculty of Medicine, Third Faculty of Medicine
- Rivaroxaban versus Enoxaparin for thromboprophylaxis after hip arthroplasty2008 | Central Library of Charles University
- Rivaroxaban versus Enoxaparin for thromboprophylaxis after hip arthroplasty2008 | Faculty of Medicine in Pilsen
- Rivaroxaban versus Enoxaparin for thromboprophylaxis after hip arthroplasty2008 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study +12008 | Faculty of Medicine in Hradec Králové
- Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study2008 | First Faculty of Medicine
- Position of rivaroxaban in current medicine2014 | Third Faculty of Medicine
- New peroral antithrombotics in the prevention and treatment of tromboembolism2012 | First Faculty of Medicine, Third Faculty of Medicine
- Antithrombotics in the prevention of cerebrovascular accidents: Part II - Significance of anticoagulant therapy2013 | First Faculty of Medicine, Third Faculty of Medicine
- Profile drug rivaroxaban - a new oral anticoagulants2014 | First Faculty of Medicine
- Edoxaban - new FXa inhibitor2017 | Publication without faculty affiliation
- Guidelines of Czech Association for Thrombosis and Haemostasis of the Czech Medical Association of J. E. Purkyně for safety treatment with new oral anticoagulants (NOAC) - dabigatran etexilate, apixaban and rivaroxaban2015 | First Faculty of Medicine
- Optimal treatment of venous thromboembolism2018 | Faculty of Medicine in Hradec Králové
- Rivaroxaban - metabolism, pharmacologic properties and drug interactions2019 | First Faculty of Medicine
- Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study2008 | Second Faculty of Medicine
- Rivaroxaban - Metabolism, Pharmacologic Properties and Drug Interactions2017 | First Faculty of Medicine
- Intravenous Thrombolysis in Patients with Acute Ischemic Stroke after a Reversal of Dabigatran Anticoagulation with Idarucizumab: A Real-World Clinical Experience2018 | Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen, Second Faculty of Medicine